CorEvitas

CorEvitas

CorEvitas operates as a clinical registry business within Thermo Fisher Scientific's PPD clinical research organization. The unit was originally established as CorEvitas before being acquired by PPD and later folded into the Thermo Fisher ecosystem upon PPD's acquisition in 2021. Its registries track longitudinal, real-world patient data to inform clinical trial design and post-market safety assessments. The strategy involves collecting standardized clinical and patient-reported data from practicing physicians across multiple disease states for pharmaceutical sponsors. Registries capture data on disease progression, treatment persistence, and outcomes, generating evidence used for label expansions, health technology assessments, and regulatory commitments. CorEvitas collaborates with Evidera, PPD's real-world evidence arm, to offer observational studies, safety monitoring, and implementation science, addressing therapeutic areas including rheumatology, dermatology, and gastroenterology. PPD employs approximately 30,000 professionals globally across clinical development, laboratory services, and real-world evidence. CorEvitas contributes within the real-world evidence segment, providing proprietary longitudinal data drawn from multiple disease-specific registries. The registries have supported academic manuscripts and conference presentations, including at ASCO 2026. No separate staffing or AUM figures are disclosed for the CorEvitas unit alone. CorEvitas holds a structural advantage through integration with PPD's broader infrastructure and Thermo Fisher's funding stability. Its registries offer longitudinal, standardized data that pharmaceutical clients cannot replicate independently. The unit's governance sits within PPD's clinical research hierarchy rather than as an independent investment vehicle, distinguishing it from venture-backed registry companies.